| ID Source | ID |
|---|---|
| PubMed CID | 9887870 |
| CHEMBL ID | 43152 |
| SCHEMBL ID | 4433724 |
| MeSH ID | M0338207 |
| Synonym |
|---|
| chembl43152 , |
| bdbm12075 |
| alpha-arylsulfonylamino carboxylate 2s |
| (2s)-2-{[4-(4-bromophenyl)benzene]sulfonamido}-3-methylbutanoic acid |
| mmp-2/mmp-3 inhibitor iii, pd166793 |
| pd-166793 |
| 199850-67-4 |
| (s)-2-(4'-bromo-[1,1'-biphenyl]-4-ylsulfonamido)-3-methylbutanoic acid |
| AKOS016004908 |
| pd 166793 |
| l-valine, n-((4'-bromo(1,1'-biphenyl)-4-yl)sulfonyl)- |
| pd-166793-0000 |
| U855L3SOXD , |
| unii-u855l3soxd |
| (s)-2-(4'-bromo-biphenyl-4-sulfonylamino)-3-methyl-butyric acid |
| GJOCABIDMCKCEG-INIZCTEOSA-N |
| (s)-2-(4'-bromobiphenyl-4-ylsulfonamido)-3-methylbutanoic acid |
| SCHEMBL4433724 |
| pd166793 , |
| DTXSID80432421 |
| n-(4'-bromo[1,1'-biphenyl]-4-sulfonyl)-l-valine |
| (s)-2-(4'-bromobiphenyl-4-ylsulfonamido)-3-methyl butanoic acid |
| mmp-2/mmp-3 inhibitor iii, pd166793 - cas 199850-67-4 |
| ((4'-bromo-[1,1'-biphenyl]-4-yl)sulfonyl)-l-valine |
| HMS3677F07 |
| HMS3413F07 |
| Q27290823 |
| (s)-2-(4'-bromo-biphenyl-4-sulfonylamino-3-methylbutyric acid) |
| mmp-2/mmp-3 inhibitor iii |
| MS-27114 |
| ZHA85067 |
| HY-107428 |
| CS-0028458 |
| (s)-2-(4'-bromo-[1,1'-biphenyl]-4-ylsulfonamido)-3-methylbutanoicacid |
| l-valine, n-[(4'-bromo[1,1'-biphenyl]-4-yl)sulfonyl]- |
| E98781 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " For this series of compounds, our objective was to systematically replace substituents appended to the biphenyl and alpha-position of 5 with structurally diverse functionalities to assess the effects these changes have on biological and pharmacokinetic activity." | ( Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. Dyer, RD; Hallak, H; Johnson, LL; Man, CF; O'Brien, PM; Ortwine, DF; Pavlovsky, AG; Picard, JA; Roth, BD; Sliskovic, DR, 2000) | 0.31 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Interstitial collagenase | Homo sapiens (human) | IC50 (µMol) | 6.0000 | 0.0002 | 0.8502 | 10.0000 | AID108742 |
| 72 kDa type IV collagenase | Homo sapiens (human) | IC50 (µMol) | 0.0147 | 0.0000 | 1.2848 | 10.0000 | AID107149; AID1796845; AID259607; AID732015 |
| 72 kDa type IV collagenase | Homo sapiens (human) | Ki | 0.0044 | 0.0000 | 0.3466 | 3.0000 | AID1796845 |
| Stromelysin-1 | Homo sapiens (human) | IC50 (µMol) | 0.0077 | 0.0000 | 1.1484 | 10.0000 | AID107488; AID1796845; AID732014 |
| Stromelysin-1 | Homo sapiens (human) | Ki | 0.0044 | 0.0003 | 0.5425 | 8.0000 | AID1796845; AID259608 |
| Matrilysin | Homo sapiens (human) | IC50 (µMol) | 7.2000 | 0.0014 | 2.0859 | 10.0000 | AID107697 |
| Matrix metalloproteinase-9 | Homo sapiens (human) | IC50 (µMol) | 7.9216 | 0.0000 | 0.7053 | 10.0000 | AID108015; AID310906 |
| Neutrophil collagenase | Homo sapiens (human) | IC50 (µMol) | 0.0040 | 0.0000 | 0.9272 | 10.0000 | AID1796845 |
| Neutrophil collagenase | Homo sapiens (human) | Ki | 0.0044 | 0.0002 | 0.1797 | 2.1000 | AID1796845 |
| Collagenase 3 | Homo sapiens (human) | IC50 (µMol) | 0.0080 | 0.0000 | 0.7675 | 10.0000 | AID109257; AID732016 |
| Matrix metalloproteinase-14 | Homo sapiens (human) | IC50 (µMol) | 0.2400 | 0.0003 | 0.7182 | 10.0000 | AID732013 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.58) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (40.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||